doi:https://doi.org/

Journal: Evidence-based Cardiology. 2013;(3): 21‑25

Read: 1038 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

. Evidence-based Cardiology. 2013;(3):21‑25. (In Russ.)

Использование инфографики авторами научных работ

References:

Fuster V., Rydeén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation - Executive Summary: A Report of the American College of Cardiology Committee for Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) [published correction appears in J Am Coll Cardiol 2007;50:562.]. J Am Coll Cardiol 2006;48:854-906.
Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
Birman-Deych E., Radford M.J., Nilasena D.S., Gage B.F. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006;37:1070-1074.
Connolly S.J., Ezekowitz M.D., Yusuf S., et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
Connolly S.J., Ezekowitz M.D., Yusuf S., et al; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876.
Granger C.B., Alexander J.H., McMurray J.J., et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
Patel M.R., Mahaffey K.W., Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
Beasley B.N., Unger E.F., Temple R. Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011;364:1788-1790.
Southworth M.R., Reichman M.E., Unger E.F. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272-1274.